LENZ - NASDAQ

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.01

-0.14%

HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$219.79M

EPS-2.8500

P/E Ratio-2.46

Earnings Date07/29/2026

305.88M

Assets

42%

3Y+551.0%

5Y+1256.0%

10Y+5097833.0%

21.54M

Total Liabilities

92%

3Y-70.0%

5Y-33.0%

10Y+868.0%

284.34M

Total Equity

39%

3Y-1276.0%

5Y-3001.0%

10Y-12920.0%

LENZ Therapeutics, Inc. Funding & Solvency Profile

LENZ · NASDAQ

Current Assets

Cash & Cash Equivalents25.18M

Net Receivables2.43M

Inventory0.00

Other Current Assets-2.43M

Total Current Assets292 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets13.53M

Total Non-Current Assets14 M

Total Assets

305.88M

Financial Health Analysis

Current Ratio

13.80x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.08x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

271 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

96% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

LENZ Therapeutics, Inc. Balance Sheet

LENZ • NASDAQ

LENZ Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	25.2M	20.2M	35.1M	44.4M	18.3M	19.8M	6K
Short-Term Investments	267.2M	188.9M	30.7M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	292.3M	209M	65.8M	44.4M	18.3M	19.8M	6K
Net Receivables	2.4M	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	329K	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	2.1M	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	2.8M	0.0	0.0	0.0	0.0	0.0
Other Current Assets	-2.4M	114K	1.5M	2.2M	16K	1.3M	0.0
Total Current Assets	292.3M	211.9M	67.2M	46.6M	18.3M	21.1M	6K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	2M	372K	279K	10K	1.5M	0.0
Other Non-Current Assets	13.5M	1.4M	2.8M	31K	2K	0.0	0.0
Total Non-Current Assets	13.5M	3.4M	3.1M	310K	12K	1.5M	0.0
Total Assets	305.9M	215.3M	70.4M	47M	18.3M	22.6M	6K
LIABILITIES
CURRENT LIABILITIES
Total Payables	4.2M	4.3M	5.7M	5.1M	460K	630K	0.0
Accounts Payable	4.2M	4.3M	5.7M	4.8M	460K	630K	0.0
Other Payables	0.0	0.0	0.0	347K	0.0	0.0	0.0
Accrued Expenses	0.0	5.6M	12.7M	4.3M	793K	466K	0.0
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	2.2M
Capital Lease Obligations (Current)	0.0	567K	137K	103K	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	347K	0.0	0.0	0.0
Other Current Liabilities	17M	0.0	0.0	0.0	0.0	31M	19K
Total Current Liabilities	21.2M	10.4M	18.5M	9.5M	1.3M	32M	2.2M
NON-CURRENT LIABILITIES
Long Term Debt	350K	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	144.4M	61.5M	31.3M	316K	0.0
Total Non-Current Liabilities	350K	814K	144.6M	61.6M	31.3M	316K	0.0
Capital Lease Obligations	0.0	1.4M	329K	250K	0.0	0.0	0.0
Total Liabilities	21.5M	11.2M	163.1M	71.1M	32.5M	32.4M	2.2M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	55.6M	0.0
Common Stock	1K	1K	10K	10K	1K	0.0	0.0
Additional Paid-In Capital	511.2M	348.9M	2.5M	1.1M	251K	0.0	0.0
Retained Earnings	-227.1M	-145M	-95.2M	-25.3M	-14.5M	-70.6M	-2.2M
Accumulated Other Comprehensive Income/Loss	242K	196K	6K	0.0	0.0	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	5.2M	0.0
Total Stockholders' Equity	284.3M	204.1M	-92.7M	-24.2M	-14.2M	-9.8M	-2.2M
Total Equity	284.3M	204.1M	-92.7M	-24.2M	-14.2M	-9.8M	-2.2M
SUMMARY
Total Liabilities & Equity	305.9M	215.3M	70.4M	47M	18.3M	22.6M	6K
Total Investments	267.2M	188.9M	30.7M	0.0	0.0	0.0	0.0
Total Debt	350K	1.4M	329K	250K	0.0	0.0	2.2M
Net Debt	-24.8M	-18.8M	-34.8M	-44.2M	-18.3M	-19.8M	2.2M
Shares Outstanding	27,910,685	27,910,685	27,910,685	27,910,685	27,910,685	27,910,685	27,910,685

SEC Filings

LENZ - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 12, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 24, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 07, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 12, 2025	December 12, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 05, 2025	November 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 08, 2025	October 08, 2025	2025	View Filing

Showing 1 to 10 of 95 filings

Related Guides

Blog Categories

Continue your LENZ research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.